- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Complaint alleged Napp-funded pharmacist asthma reviews created a conflict of interest and switched patients to Flutiform. Panel found no evidence to support…
Shire was held responsible for a third-party market research email that amounted to disguised promotion (Revestive) and for inappropriate MSL visit KPIs…
Pfizer’s separate reply-paid card offering an Arthrotec memory stick was treated as standalone promotion and breached the Code because it omitted the…
Sanofi-Aventis’ Lantus mailer drew complaints about cost, hypoglycaemia and weight claims vs Levemir. Cost claim: no breach. Hypoglycaemia headline and weight equivalence…
Roche alleged pre-licence promotion of Tykerb via an international journal ‘teaser’ ad and UK media coverage implying superiority vs Herceptin. Panel found…
Ex-employee alleged misleading Casodex 150 promotion and pressure on call metrics. PMCPA found breaches for “equivalent efficacy to castration” and inadequate Code…
A GP journal insert presented as an “unrestricted educational grant” was ruled promotional, misleading and disguised. Data were selectively presented (incl. suppressed-zero…
A PCT complainant alleged a Champix “launch update” meeting invite primed stop-smoking advisers to drive public demand. PMCPA found attendees were appropriate…
A contract rep complained about high call-rate expectations. The Panel found an agency email advocated increased frequency likely to breach the Code,…
Shire was accused of breaching an undertaking by still using a paper previously linked to a misleading ad. PMCPA found that distributing…
PMCPA case AUTH/3000/12/17 (Director v Roche) concerning clinical trial disclosure for Gazyvaro. Outcome: no breach; matter outwith the scope of the Code.
PMCPA Director review into a clinical trial disclosure matter relating to Zinforo (Teflaro in the USA). The case was ruled outwith the…
AbbVie was found in breach for failing to accurately declare its involvement in an Embrace Stars poster and for using uncertified case-study…
A Pulse ad claimed Relvar Ellipta was “superior to other ICS/LABAs” based on the Salford Lung Study, but lacked key context and…
Novartis’ Nicotinell journal ad was ruled misleading for implying afternoon/evening craving “peaks” and for a “quit rates up to four times” claim…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.